Hologic Announces Financial Results for Fourth Quarter of Fiscal 2022

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2022




Hologic Announces Financial Results for Fourth Quarter of Fiscal 2022

– Revenue of $953 Million, GAAP Diluted EPS of $0.47, and Non-GAAP Diluted EPS of $0.82 All Exceed Expectations –

– Global Organic Molecular Diagnostics Revenue Grows 17% in Constant Currency, ex-COVID-19 –

– Fiscal 2023 Financial Guidance Anticipates Strong Growth in All Core Businesses –

MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #earnings–Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 24, 2022.

“In our fourth quarter of fiscal 2022, Hologic delivered excellent results that significantly exceeded expectations, topping off another tremendous year,” said Steve MacMillan, the Company’s chairman, president and chief executive officer. “Fiscal 2022 was outstanding for Hologic. We dramatically strengthened our base businesses, responded with agility to the world’s COVID testing needs, and most importantly, helped more and more women around the world. Entering 2023, we see unprecedented strength across each of our core businesses and all are uniquely poised to deliver low double-digit constant currency organic revenue growth ex. COVID-19 for the year.”

Recent Highlights

  • Revenue of $953.3 million decreased (27.6%) for the quarter, or (25.6%) in constant currency, primarily driven by lower sales of COVID-19 assays and supply chain challenges related to semiconductor chips in our Breast Health business compared to the prior year period. Revenue, however, was significantly higher than the Company’s guidance of $840 to $870 million provided last quarter.
  • Diagnostics revenue decreased (37.8%), or (35.6%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period.
  • Excluding COVID-19 revenues, Diagnostics revenue grew 11.1% on an organic, constant currency basis.
  • Molecular Diagnostics revenue declined (43.2%), or (41.3%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period.
  • Excluding COVID-19 revenues, Molecular Diagnostics revenue grew 17.2% on an organic, constant currency basis.
  • Breast Health revenue, as expected, declined (17.7%), or (16.0%) in constant currency, primarily due to lower gantry revenue resulting from semiconductor chip shortages. The Company believes gantry demand remains strong and expects chip supply to improve throughout fiscal 2023.
  • Surgical revenue grew 9.3%, or 11.4% in constant currency, primarily driven by improved procedure volume as COVID prevalence declined.
  • Cash flow from operations remained very strong in the fourth quarter at $168.7 million.
  • The Company repurchased 2.5 million shares of its stock for $175.1 million in the quarter and 7.7 million shares for $542.1 million for the full year.
  • On September 21, 2022, Hologic released findings from the second annual Hologic Global Women’s Health Index, one of the world’s largest studies of women’s well-being.
  • On September 22, 2022, Hologic’s Board of Directors authorized a new stock repurchase program, with a five-year term, to repurchase up to $1.0 billion of the Company’s outstanding common stock.

Key financial results for the fiscal fourth quarter are shown in the table below.

 

GAAP

Non-GAAP

 

Q4’22

Q4’21

Change

Increase (Decrease)

Q4’22

Q4’21

Change

Increase (Decrease)

Revenues

$953.3

 

$1,316.6

 

(27.6%)

 

$953.3

 

$1,316.6

 

(27.6%)

Gross Margin

54.0%

 

62.9%

 

(890 bps)

 

62.5%

 

69.4%

 

(690 bps)

Operating Expenses

$373.7

 

$388.6

 

(3.8%)

 

$329.9

 

$353.2

 

(6.6%)

Operating Margin

14.8%

 

33.4%

 

(1,860 bps)

 

27.9%

 

42.5%

 

(1,460 bps)

Net Margin

12.5%

 

25.0%

 

(1,250 bps)

 

21.8%

 

31.6%

 

(980 bps)

Diluted EPS

$0.47

 

$1.28

 

(63.3%)

 

$0.82

 

$1.61

 

(49.1%)

Throughout this press release, all dollar figures are in millions, except EPS, unless otherwise noted. Some totals may not foot due to rounding. Unless otherwise noted, all results are compared to the corresponding prior year period. Non-GAAP results exclude certain cash and non-cash items as discussed under “Use of Non-GAAP Financial Measures.” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period. Our fiscal fourth quarter organic revenue results exclude the divested Blood Screening business, as well as the acquired Bolder business. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition.

Revenue Detail

 

 

 

 

Increase (Decrease)

$ in millions

Q4’22

Q4’21

Global Reported Change

Global

Constant Currency Change

U.S.

Reported Change

International

Reported

Change

International

Constant Currency Change

Diagnostics

 

 

 

 

 

 

 

Cytology and Perinatal

$112.8

 

$116.0

 

(2.8%)

 

1.5%

 

(1.0%)

 

(5.7%)

 

5.8%

Molecular Diagnostics

$400.2

 

$704.5

 

(43.2%)

 

(41.3%)

 

(37.4%)

 

(55.3%)

 

(49.6%)

Blood Screening

$7.9

 

$16.3

 

(51.5%)

 

(51.5%)

 

(51.5%)

 

N/A

 

N/A

Total Diagnostics

$520.9

 

$836.8

 

(37.8%)

 

(35.6%)

 

(33.1%)

 

(47.6%)

 

(40.9%)

Organic Diagnostics ex. COVID-19

$325.4

 

$301.8

 

7.8%

 

11.1%

 

7.8%

 

7.8%

 

20.6%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Breast Health

 

 

 

 

 

 

 

 

 

 

 

 

 

Breast Imaging

$212.0

 

$265.5

 

(20.2%)

 

(18.4%)

 

(17.8%)

 

(29.1%)

 

(20.5%)

Interventional Breast Solutions

$63.1

 

$68.7

 

(8.2%)

 

(6.7%)

 

(9.6%)

 

(1.9%)

 

6.5%

Total Breast Health

$275.1

 

$334.2

 

(17.7%)

 

(16.0%)

 

(16.1%)

 

(24.1%)

 

(15.6%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GYN Surgical

$133.3

 

$122.0

 

9.3%

 

11.4%

 

8.7%

 

11.7%

 

23.8%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Skeletal Health

$24.0

 

$23.6

 

1.7%

 

3.7%

 

0.5%

 

4.5%

 

10.9%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

$953.3

 

$1,316.6

 

(27.6%)

 

(25.6%)

 

(23.4%)

 

(38.6%)

 

(31.3%)

Organic (definition above)

$942.1

 

$1,300.3

 

(27.5%)

 

(25.5%)

 

(23.1%)

 

(38.8%)

 

(31.5%)

Organic ex. COVID-19

$754.4

 

$781.6

 

(3.5%)

 

(1.1%)

 

(3.2%)

 

(4.4%)

 

6.4%

Other Financial Highlights

  • U.S. revenue of $728.6 million decreased (23.4%). International revenue of $224.7 million decreased (38.6%), or (31.3%) in constant currency.
  • GAAP gross margin of 54.0% decreased (890) basis points. Non-GAAP gross margin of 62.5% decreased (690) basis points. The decrease in gross margin was primarily due to a decline in COVID-19 assay sales compared to the prior year period and lower capital equipment sales due to supply chain challenges related to semiconductor chip shortages impacting our Breast Health business.
  • GAAP operating margin of 14.8% decreased (1,860) basis points. Non-GAAP operating margin of 27.9% decreased (1,460) basis points. The decrease in operating margin was primarily due to a decline in COVID-19 assay sales compared to the prior year period and lower capital equipment sales due to supply chain challenges related to semiconductor chip shortages impacting our Breast Health business.
  • GAAP net income of $118.7 million decreased (63.9%). Non-GAAP net income of $207.5 million decreased (50.1%). Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) was $299.5 million, a decrease of (48.0%).
  • COVID-19 revenues, which consist of COVID-19 assay revenue of $150.7 million, and other COVID-19 related revenue and revenue from discontinued products of $37.0 million, decreased (63.8%), or (62.3%) in constant currency.
  • Total principal debt outstanding at the end of the fourth quarter was $2.85 billion. The Company ended the quarter with cash and equivalents of $2.3 billion, and a net leverage ratio (net debt over adjusted EBITDA) of 0.2.
  • On a trailing 12-month basis, adjusted Return on Invested Capital (ROIC) was 22.3%, a decrease of (1,030) basis points compared to the prior year period.

Financial Guidance for the First Quarter and Full-Year Fiscal 2023

“Our fiscal fourth quarter 2022 caps off a year of exceptional top-line and bottom-line financial performance,” said Karleen Oberton, Hologic’s chief financial officer. “In our fiscal 2023, we expect continued strength in our base Diagnostics and Surgical businesses as well as a strong rebound in our Breast Health business over the course of the year.”

Hologic’s financial guidance for the first quarter and full year 2023 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 19.0%, and diluted shares outstanding of 252 million for the full year. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2023 as in fiscal 2022. Organic revenue guidance is in constant currency and excludes the divested Blood Screening business. Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition. Therefore, in fiscal 2023, Bolder is excluded from organic revenue in the fiscal first quarter, while Biotheranostics, Diagenode, Mobidiag, and Acessa are part of organic revenue for all of fiscal 2023.

 

Current Guidance

 

Guidance $

Reported %

Increase

(Decrease)

Constant Currency

% Increase

(Decrease)

Organic % Increase

(Decrease)

Fiscal 2023

 

 

 

 

Revenue

$3,700 – $3,900

(23.9%) to (19.8%)

(22.1%) to (18.0%)

(22.0%) to (17.9%)

GAAP EPS

$2.51 – $2.81

(51.1%) to (45.2%)

 

 

Non-GAAP EPS

$3.30 – $3.60

(45.2%) to (40.2%)

 

 

 

 

 

 

 

Q1 2023

 

 

 

 

Revenue

$940 – $990

(36.1%) to (32.7%)

(33.9%) to (30.5%)

(34.2%) to (30.8%)

GAAP EPS

$0.60 – $0.70

(69.2%) to (64.1%)

 

 

Non-GAAP EPS

$0.80 – $0.90

(63.1%) to (58.5%)

 

 

 

This guidance assumes low double-digit constant currency organic revenue growth ex. COVID-19 in each division for full-year fiscal 2023.

Use of Non-GAAP Financial Measures

The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding COVID-19, non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; and adjusted EBITDA. Organic revenue for the fiscal fourth quarter of 2022 excludes the divested Blood Screening business, as well as the acquired Bolder business. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition. Organic revenue excluding COVID-19 revenues is organic revenue less COVID assay revenue, COVID related sales of instruments, COVID related revenue from Diagenode and Mobidiag, collection kits and ancillaries, as well as license revenue, and revenues from discontinued products. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill, intangible assets and equipment; (ii) adjustments to record contingent consideration at fair value; (iii) additional expenses resulting from the purchase accounting adjustment to record inventory at fair value; (iv) restructuring and divestiture charges and facility closure and consolidation charges, including accelerated depreciation, and costs incurred to integrate acquisitions (including retention, transaction bonuses, legal and professional consulting services) and separate divested businesses from existing operations; (v) expenses related to the divested Cynosure business incurred subsequent to the disposition date primarily related to indemnification provisions for legal and tax matters; (vi) transaction related expenses for divestitures and acquisitions; (vii) third-party expenses incurred related to implementing the European MDR/IVDR requirements and obtaining the appropriate approvals for its existing products; (viii) debt extinguishment losses and related transaction costs; (ix) the unrealized (gains) losses on the mark-to-market of foreign currency contracts for which the Company has not elected hedge accounting; (x) litigation settlement charges (benefits) and non-income tax related charges (benefits); (xi) other-than-temporary impairment losses on investments and realized gains and losses resulting from the sale of investments; (xii) the one-time discrete impacts related to internal restructurings and non-operational items; (xiii) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company’s core business results; and (xiv) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others.

The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Hologic’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic’s business.

Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Conference Call and Webcast

Hologic’s management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the fourth quarter of fiscal 2022. Interested participants may listen to the call by dialing 800-263-0877 (in the U.S. and Canada) or +1 323-794-2094 (for international callers) and referencing access code 9021328. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. The Company will also provide a live webcast of the call at investors.hologic.com. A replay of the call will be available at investors.hologic.com approximately two hours after the call ends through Wednesday, November 30, 2022.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company’s strategies, positioning, resources, capabilities, and expectations for future performance; and the Company’s outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect the Company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the severity and duration of the COVID-19 pandemic and its impact on the U.S. healthcare system, the U.S. economy and worldwide economy; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic; disruption of supply chains, including the availability of critical raw materials and components, including semiconductor chips, or more commonly referred to as chips, as well as cost inflation in materials, packaging and transportation; manufacturing risks, including the Company’s reliance on a single or limited source of supply for key components, the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; continued demand for the Company’s COVID-19 TMA assay; the Company’s ability to manufacture, on a scale necessary to meet demand, its COVID-19 TMA assay as well as the Panther systems on which the assay runs; U.S., European and general worldwide economic conditions, including recession concerns, trade relations, and related uncertainties; the Company’s ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the Company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company’s ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, and the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company’s international activities and businesses; the early stage of market development for certain of the Company’s products; the Company’s leverage risks, including the Company’s obligation to meet payment obligations and financial covenants associated with its debt; cybersecurity risks; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.

The risks included above are not exhaustive. Other factors that could adversely affect the Company’s business and prospects are described in the filings made by the Company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

SOURCE: Hologic, Inc.

HOLOGIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In millions, except number of shares, which are reflected in thousands, and per share data)

 

 

Three Months Ended

Years Ended

 

September 24,

2022

September 25,

2021

September 24,

2022

September 25,

2021

 

 

 

 

 

Revenues:

 

 

 

 

Product

$

782.6

 

 

$

1,137.9

 

 

$

4,191.2

 

 

$

4,967.3

 

Service and other

 

170.7

 

 

 

178.7

 

 

 

671.6

 

 

 

665.0

 

Total revenues

 

953.3

 

 

 

1,316.6

 

 

 

4,862.8

 

 

 

5,632.3

 

 

 

 

 

 

 

 

 

Cost of revenues:

 

 

 

 

 

 

 

Product

 

259.1

 

 

 

316.0

 

 

 

1,166.1

 

 

 

1,205.1

 

Amortization of acquired intangible assets

 

72.6

 

 

 

82.5

 

 

 

295.7

 

 

 

276.7

 

Impairment of acquired intangible assets

 

8.3

 

 

 

 

 

 

17.4

 

 

 

 

Service and other

 

98.7

 

 

 

90.0

 

 

 

386.2

 

 

 

354.7

 

 

 

 

 

 

 

 

 

Gross profit

 

514.6

 

 

 

828.1

 

 

 

2,997.4

 

 

 

3,795.8

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

76.0

 

 

 

76.5

 

 

 

283.4

 

 

 

276.3

 

Selling and marketing

 

159.2

 

 

 

159.1

 

 

 

630.3

 

 

 

561.2

 

General and administrative

 

97.3

 

 

 

135.4

 

 

 

407.7

 

 

 

433.2

 

Amortization of acquired intangible assets

 

12.0

 

 

 

11.5

 

 

 

45.2

 

 

 

42.2

 

Impairment of acquired intangible asset

 

27.7

 

 

 

 

 

 

27.7

 

 

 

 

Contingent consideration fair value adjustments

 

 

 

 

3.4

 

 

 

(39.5

)

 

 

(6.7

)

Restructuring and divestiture charges

 

1.5

 

 

 

2.7

 

 

 

2.4

 

 

 

9.3

 

Total operating expenses

 

373.7

 

 

 

388.6

 

 

 

1,357.2

 

 

 

1,315.5

 

 

 

 

 

 

 

 

 

Income from operations

 

140.9

 

 

 

439.5

 

 

 

1,640.2

 

 

 

2,480.3

 

Interest income

 

9.4

 

 

 

0.2

 

 

 

12.9

 

 

 

1.4

 

Interest expense

 

(24.1

)

 

 

(22.7

)

 

 

(95.1

)

 

 

(93.6

)

Debt extinguishment loss

 

 

 

 

 

 

 

(0.7

)

 

 

(21.6

)

Other income (expense), net

 

17.2

 

 

 

(6.4

)

 

 

30.9

 

 

 

(5.4

)

 

 

 

 

 

 

 

 

Income before income taxes

 

143.4

 

 

 

410.6

 

 

 

1,588.2

 

 

 

2,361.1

 

Provision for income taxes

 

24.7

 

 

 

81.8

 

 

 

286.2

 

 

 

491.4

 

 

 

 

 

 

 

 

 

Net income

$

118.7

 

 

$

328.8

 

 

$

1,302.0

 

 

$

1,869.7

 

 

 

 

 

 

 

 

 

Net loss attributable to noncontrolling interest

 

 

 

 

 

 

 

 

 

 

(1.8

)

Net income attributable to Hologic

$

118.7

 

 

$

328.8

 

 

$

1,302.0

 

 

$

1,871.5

 

 

 

 

 

 

 

 

 

Net income per common share attributable to Hologic:

 

 

 

 

 

 

 

Basic

$

0.47

 

 

$

1.29

 

 

$

5.18

 

 

$

7.28

 

Diluted

$

0.47

 

 

$

1.28

 

 

$

5.13

 

 

$

7.21

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding:

 

 

 

 

 

 

 

Basic

 

250,278

 

 

 

254,876

 

 

 

251,527

 

 

 

257,046

 

Diluted

 

252,560

 

 

 

257,710

 

 

 

253,845

 

 

 

259,706

 

HOLOGIC, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In millions)

 

 

September 24, 2022

September 25, 2021

ASSETS

 

 

 

 

 

Current assets:

 

 

Cash and cash equivalents

$

2,339.5

$

1,170.3

Accounts receivable, net

 

617.6

 

942.7

Inventory

 

623.7

 

501.2

Other current assets

 

281.2

 

554.5

Total current assets

 

3,862.0

 

3,168.7

 

 

 

Property, plant and equipment, net

 

481.6

 

564.7

Goodwill and intangible assets

 

4,517.1

 

4,940.8

Other assets

 

210.5

 

245.7

Total assets

$

9,071.2

$

8,919.9

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

Current portion of long-term debt

$

15.0

$

313.0

Accounts payable and accrued liabilities

 

736.2

 

815.8

Deferred revenue

 

186.5

 

198.0

Total current liabilities

 

937.7

 

1,326.8

 

 

 

Long-term debt, net of current portion

 

2,808.4

 

2,712.2

Deferred income taxes

 

90.8

 

250.5

Other long-term liabilities

 

358.1

 

411.8

Total stockholders’ equity

 

4,876.2

 

4,218.6

Total liabilities and stockholders’ equity

$

9,071.2

$

8,919.9

Contacts

Ryan Simon

Vice President, Investor Relations

Ryan.Simon@hologic.com
(858) 410-8514

Francis Pruell

Director, Investor Relations

Francis.Pruell@hologic.com
(508) 263-8628

Read full story here